Navigation Links
Volcano Announces Record Fourth Quarter Revenues
Date:2/21/2013

nefits related to a portion of the company's deferred tax valuation allowance referenced above.

"We continued to execute our growth strategy in 2012, delivering a double digit increase in revenues, led by a 45 percent increase in annual revenues on a constant currency basis in our FFR (Fractional Flow Reserve) disposable business. Our FFR technology is emblematic of our Functional PCI strategy that provides solutions for healthcare providers seeking both improved clinical and economic outcomes," said Scott Huennekens, president and chief executive officer.

"At the same time, we continued to position the company for long-term growth by targeting addressable markets that are double the size of those we address today through the growth of our base business, development of our pipeline and implementation of business expansion strategies."

"During the fourth quarter," he continued, "we realized two important milestones in this strategy with our acquisitions of Sync-RX and Crux Biomedical. Sync-RX provides us advanced imaging technology that we will incorporate into our multi-modality platform, while Crux brings Volcano a novel inferior vena cava (IVC) filter and related offerings, and is indicative of our strategy to move beyond intravascular imaging to a wide variety of diagnostic and therapeutic solutions for both coronary and peripheral applications."

Guidance for 2013

The company provided guidance for fiscal 2013. It expects revenues will be in the range of $422.0-$428.0 million. It expects gross margins will be in the range of 65-66 percent and operating expenses will be 61-62 percent of revenues. The company expects a net loss on a GAAP basis of $0.10-$0.14 per share in 2013 and non-GAAP net income of $0.16-$0.20 per diluted share in 2013. Non-GAAP results exclude acquisition-related expenses, amortization of intangibles and non-cash interest expense. The company expects weighted average basic shares in 2013 will be approximately
'/>"/>

SOURCE Volcano Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
2. Volcano Corporation Prices Offering Of $400 Million 1.75% Convertible Senior Notes Due 2017
3. Volcano Corporation To Offer $350 Million Convertible Senior Notes Due 2017
4. Volcano Corporation Signs Agreement to Acquire Sync-Rx Ltd.
5. Volcano Corporation Presentation At Piper Jaffray Conference To Be Webcast
6. Fish & Richardson Prevails in Patent Infringement Trial for Volcano Corporation
7. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
8. Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude Medical
9. Volcano Corporation Presentation At Stifel Nicolaus Conference To Be Webcast
10. FAME 2 Published in the New England Journal of Medicine, Volcano participates in the $84M NIH-Sponsored ISCHEMIA Trial
11. Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... SAN FRANCISCO , Aug. 31, 2015  On ... District of Oregon denied motions ... Inc. (NASDAQ: GALE ) and certain of its ... had facilitated a "pump and dump" scheme to artificially ... trading period while the stock price was inflated, sold ...
(Date:8/31/2015)... 31, 2015  Regulatory affairs professionals work at ... are often strict and legislation is ever-changing. The ... for professionals who have a deep understanding of ... product lifecycle and demonstrate its use across various ... California, Irvine Extension , in partnership with the ...
(Date:8/31/2015)... Aug. 31, 2015 Regen BioPharma, Inc. (OTCBB: ... a novel means of delivering its patented (US ... liver tumors utilizing a clinically approved formulation as ... hurdles with gene silencing therapeutics in which the ... the whole body.  By utilizing a local delivery ...
Breaking Medicine Technology:Galena Biopharma, Inc. Stock Alert: Schubert Firm Investigates Potential Breaches of Fiduciary Duty 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3
... Ore.--(BUSINESS WIRE)--Jul 10, 2007 - AVI BioPharma, Inc.,(Nasdaq:AVII) ... target patient enrollment and released six-month,follow-up data from ... trial, currently being held in Germany, was designed ... Resten-MP(TM), when,used in conjunction with the placement of ...
... Fail to Demonstrate Meaningful Placebo Adjusted Weight,Loss; ... July 09, 2007 /PRNewswire-FirstCall/ -- Manhattan,Pharmaceuticals, Inc. ... 2a clinical trials of oral Oleoyl-estrone (OE). ... one,in common obesity and the other in ...
Cached Medicine Technology:AVI BioPharma Partner Cook Medical Announces Completion of Patient,Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of,Cardiovascular Disease 2Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 2Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 3Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 4
(Date:9/1/2015)... , ... September 01, 2015 , ... September is Baby ... manufacturers use safety labels and stickers to keep little ones' safety top of mind ... Safety Month has a particular focus. According to the JPMA's Baby Safety Zone website, ...
(Date:8/31/2015)... ... September 01, 2015 , ... AthleticTraining.com, provider of CEUs for ... of new premium on-demand video Evidence Based Practice courses that ... 2014 must complete 50 CEUs before December 31, 2015, which must include at ...
(Date:8/31/2015)... ... August 31, 2015 , ... Sculpted Contours Luxury Medical ... Women of Power and Influence by Modern Luxury’s The Atlantan Magazine. , ... as well as Kathy King. Her idea and vision to bring to Atlanta ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... Southern Vacation ... – has teamed up with fellow South Walton property management company, 360 ... extreme poverty in remote parts of the world. The two companies will collect any ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... management, recently opened registration for the company’s second Introduction to Hyperbaric Medicine Course. ... October 15-18, 2015 aboard the Queen Mary Hotel in Long Beach, CA. The ...
Breaking Medicine News(10 mins):Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:Evidence Based Practice Courses: CEUs For Athletic Trainers Just Released 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 3Health News:Southern Vacation Rentals Partners with the Sonder Project 2Health News:Southern Vacation Rentals Partners with the Sonder Project 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4
... (NSAIDs), such as aspirin and ibuprofen, may reduce serum ... and hence may alter the detection of prostate cancer ... conclusion of a new study in the October 15, ... journal of the American Cancer Society. , Chronic ...
... and ibuprofen appear to lower a man,s PSA level, the ... a man is at risk of prostate cancer. , But ... in the journal Cancer , caution that men shouldn,t ... just yet. , "We showed that men who regularly ...
... also been linked recently to patient deaths , , ... once-a-week formulation of the injectable diabetes drug Byetta ... twice-a-day formulation, researchers report. , "Besides obvious improved ... remarkable advantage of both improved efficacy on glucose ...
... Pathologists Discuss the Latest Developments in Molecular,Testing and ... The practice of,pathology is at a transformation point. ... change the way patients are treated. Digital,slides and ... The College of American Pathologists is taking a ...
... ROCKVILLE, Md., Sept. 5 The Health Resources,and ... grants to,increase and improve medical services at the ... Bush,s historic expansion of the,health center network, whose ... Americans than ever before," HRSA,Administrator Elizabeth M. Duke ...
... Researchers explain how theoretical ,anti-cloak, could bring objects out ... Just in case someone develops a cloak of invisibility, ... to uncloak the objects it hides. , According to ... materials underneath an invisibility cloak would allow invisible objects ...
Cached Medicine News:Health News:Anti-inflammatory drugs may mask prostate cancer marker 2Health News:Common painkillers lower levels of prostate cancer biomarker 2Health News:Once-Weekly Diabetes Drug Boosts Blood Sugar Control 2Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2
Open blade design with aspiration capabilities for removing fluids from the operative site. 19 gauge wire....
Designed to provide open approaches of the keratome to the cornea for either the left or right eye. Lightweight wire design adds to the comfort of the instrument when in place....
Solid 14 mm free-swinging blades, suture posts, and stabilizing disk. Dull finish....
Designed for use with foster enucleation snare (E3670). Package of 12 stainless steel wires. Overall length 5.3 inches....
Medicine Products: